Quality-of-life measurement in randomized clinical trials in breast cancer: An updated systematic review (2001-2009)

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages 178-231

  Lemieux, Julie ^a,b   Goodwin, Pamela J ^c   Bordeleau, Louise J ^d   Lauzier, Sophie ^b,e   Théberge, Valérie ^a,b,d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BENDAMUSTINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CARMOFUR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ESTRADIOL; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; MILTEFOSINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; UFT; UNINDEXED DRUG;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; LYMPH NODE DISSECTION; MEDLINE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SELF REPORT; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HUMANS; MEDICAL RECORDS; MORBIDITY; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79551703738     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq508     Document Type: Review

References (249)

1. WHOQOL group. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993;2(2):153-159.
2. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr., Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst. 1989;81(7):485-495. (Pubitemid 19102216)
3. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock [review] [93 refs]. J Natl Cancer Inst. 2003;95(4):263-281. (Pubitemid 36336477)
4. Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer. 2007;109(4):787-795. (Pubitemid 46233242)
5. Paul N, Pater J, Whitehead M, Sadura A. Methods of toxicity data collection: an evaluation of the relative effectiveness of the case report flow sheet (FS), the patient symptom diary (SD), and the quality of life questionnaire (QLQ). Control Clin Trials. 1991;12(5):648.
6. US Department of Health and Human Services FaDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads /Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed December 2009.
7. Efficace F, Bottomley A, Van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer. 2003;97(2):377-388. (Pubitemid 36133805)
8. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24(19):3178-3186. (Pubitemid 46646225)
9. Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007;18(12):1935-1942. (Pubitemid 350286228)
10. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.
11. De Haes JC, Curran D, Aaronson NK, Fentiman IS. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer. 2003;39(7):945-951. (Pubitemid 36428626)
12. Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91(1):38-43. (Pubitemid 38122047)
13. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312-4321. (Pubitemid 46209968)
14. Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93 [see Rudenstam CM, Zahrieh D, comment]. J Clin Oncol. 2006;24(3):337-344. (Pubitemid 46630451)
15. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599-609. (Pubitemid 43904843)
16. Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247(2):207-213. (Pubitemid 351156760)
17. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34(5):508-513. (Pubitemid 351514885)
18. Rayan G, Dawson LA, Bezjak A, et al. Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy [see comment]. Int J Radiat Oncol, Biol, Phys. 2003;55(1):154-161. (Pubitemid 36020355)
19. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963-970.
20. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254-264. (Pubitemid 46341474)
21. Prescott RJ, Kunkler IH, Williams LJ, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess. 2007;11(31):1.
22. Pignol J-P, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26(13):2085-2092.
23. Classe JM, Berchery D, Campion L, Pioud R, Dravet F, Robard S. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. Br J Surg. 2006;93(7):820-824. (Pubitemid 44035253)
24. International Breast Cancer Study G. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial [see comment] [erratum appears in J Natl Cancer Inst 2002 Sep 4;94(17): 1339]. J Natl Cancer Inst. 2002;94(14)1054-1065.
25. Bernhard J, Zahrieh D, Coates AS, et al. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004;91(11):1893-1901. (Pubitemid 40065517)
26. De Haes H, Olschewski M, Kaufmann M, et al. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group [see comment]. J Clin Oncol. 2003;21(24):4510-4516. (Pubitemid 46594020)
27. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20(24):4628-4635. (Pubitemid 36025278)
28. Groenvold M, Fayers PM, Petersen MA, Mouridsen HT. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat. 2006;98(3):275-284. (Pubitemid 44195597)
29. Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients-the International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007;25(3):263-270. (Pubitemid 350003014)
30. The Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst. 2007;99(7):516-525.
31. Del Mastro L, Costantini M, Morasso G, et al. Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. Eur J Cancer. 2002;38(3):359-366. (Pubitemid 34121963)
32. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724-1733. (Pubitemid 41782282)
33. Tominaga T, Kimura M, Asaga T, et al. 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. Oncol Rep. 2004;12(4):797-803.
34. Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401 [see comment]. J Clin Oncol. 2003;21(19):3659-3664. (Pubitemid 46594060)
35. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356(9239):1384-1391.
36. Land SR, Kopec JA, Yothers G, et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat. 2004;86(2):153-164. (Pubitemid 38988018)
37. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19(4):931-942. (Pubitemid 32176267)
38. Bottomley A, Therasse P, Piccart M, et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial [see comment]. Lancet Oncol. 2005;6(5):287-294. (Pubitemid 40590265)
39. Efficace F, Therasse P, Piccart MJ, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol. 2004;22(16):3381-3388. (Pubitemid 41103697)
40. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study [review] [33 refs]. J Clin Oncol. 2003;21(5):843-850. (Pubitemid 46606444)
41. Peppercorn J, Herndon J II, Kornblith AB, et al. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005;104(8):1580-1589. (Pubitemid 41437420)
42. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23(10):2191-2200. (Pubitemid 46222235)
43. Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study [see comment]. J Clin Oncol. 2005;23(33):8296-8304.
44. Buijs C, Rodenhuis S, Seynaeve CM, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol. 2007;25(34):5403-5409. (Pubitemid 350232216)
45. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313. (Pubitemid 40740554)
46. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17(8):1205-1212. (Pubitemid 44288210)
47. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-1862. (Pubitemid 44664643)
48. Earl HM, Hiller L, Dunn JA, et al. NEAT: National Epirubicin Adjuvant Trial-toxicity, delivered dose intensity and quality of life. Br J Cancer. 2008;99(8):1226-1231.
49. Malinovszky KM, Gould A, Foster E, et al. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer. 2006;95(12):1626-1631. (Pubitemid 44950786)
50. The Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst. 2007;99(7):506-515.
51. Bernhard J, Zahrieh D, Zhang JJ, et al. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer. 2008;98(1):25-33.
52. Marino P, Roché H, Biron P, et al. Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study. Value Health. 2008;11(4):709-718. (Pubitemid 352036653)
53. Watanabe T, Sano M, Takashima S, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol. 2009;27(9):1368-1374.
54. Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2003;21(9):1836-1844. (Pubitemid 46638597)
55. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer. 2006;42(7):895-904. (Pubitemid 44294521)
56. Pagani O, Gelber S, Price K, et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004;15(12):1749-1759.
57. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261-4271. (Pubitemid 41185147)
58. Buzdar AU. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update [review] [23 refs]. Clin Breast Cancer. 2004;5(suppl 1):S6-S12.
59. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273-284. (Pubitemid 44707921)
60. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
61. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931-6940.
62. Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast cancer research and treatment. 2007;105(suppl 1):45-53.
63. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008;26(12):1956-1964.
64. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-1802. (Pubitemid 37362955)
65. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271. (Pubitemid 41535367)
66. Francini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006;95(2):153-158. (Pubitemid 44050914)
67. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol. 2007;25(30):4765-4771. (Pubitemid 350086479)
68. Mamounas EP, Jeong J-H, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965-1971.
69. Leonard R, Hardy J, Van Tienhoven G, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol. 2001;19(21):4150-4159. (Pubitemid 33049533)
70. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-2823. (Pubitemid 34651510)
71. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial [see comment] [erratum appears in J Clin Oncol. 2003 May 15;21(10):2048]. J Clin Oncol. 2003;21(6):968-975. (Pubitemid 46594123)
72. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) [see comment]. J Clin Oncol. 2003;21(4):588-592. (Pubitemid 46621890)
73. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004;15(10):1517-1526. (Pubitemid 39409743)
74. Conte PF, Guarneri V, Bruzzi P, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results from the Gruppo Oncologico Nord Ovest randomized trial. Cancer. 2004;101(4):704-712. (Pubitemid 39030924)
75. Bottomley A, Biganzoli L, Cufer T, et al. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol. 2004;22(13):2576-2586. (Pubitemid 41103744)
76. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20(14):3114-3121. (Pubitemid 34791101)
77. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22(11):2061-2068. (Pubitemid 41095138)
78. Reyno L, Seymour L, Tu D, et al. Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol. 2004;22(2):269-276. (Pubitemid 41095091)
79. Lin C-C, Chang A-P, Chen M-L, Cleeland CS, Mendoza TR, Wang XS. Validation of the Taiwanese version of the Brief Fatigue Inventory. J Pain Symptom Manage. 2006;32(1):52-59. (Pubitemid 43996831)
80. Von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs. 2005;16(8):871-877. (Pubitemid 41215753)
81. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23(24):5542-5551.
82. Karamouzis MV, Ioannidis G, Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care. 2007;16(5):433-438.
83. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 2008;26(1):37-43.
84. Cassier PA, Chabaud S, Trillet-Lenoir V, et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat. 2008;109(2):343-350. (Pubitemid 351658936)
85. Hopwood P, Watkins J, Ellis P, Smith I. Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer. Breast J. 2008;14(3):228-235. (Pubitemid 351678053)
86. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009;115(1):87-99.
87. Maniadakis N, Dafni U, Fragoulakis V, et al. Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial. Ann Oncol. 2009;20(2):278-285.
88. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20(14):3106-3113. (Pubitemid 34791100)
89. Eiermann W, International Herceptin Study G. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12(suppl 1):S57-S62. (Pubitemid 32750586)
90. Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol. 1999;26(4 Suppl. 12):84-88. (Pubitemid 29411437)
91. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. (Pubitemid 32222155)
92. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792-799. (Pubitemid 46224178)
93. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
94. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate [see comment]. J Clin Oncol. 2001;19(14):3357-3366. (Pubitemid 32642188)
95. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment [see comment]. J Clin Oncol. 2002;20(16):3396-3403.
96. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial [see comment]. J Clin Oncol. 2002;20(16):3386-3395.
97. Thomas R. Examining quality of life issues in relation to endocrine therapy for breast cancer. Am J Clin Oncol. 2003;26(4):S40-S44. (Pubitemid 36966422)
98. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M. Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol). 2004;16(7):485-491. (Pubitemid 39232947)
99. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26(4):592-598. (Pubitemid 351264353)
100. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664-1670.
101. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302(7):774-780.
102. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 2004;40(11):1704- 1712. (Pubitemid 38902906)
103. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405. (Pubitemid 37185286)
104. Scott C, Suh J, Stea B, Nabid A, Hackman J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol. 2007;30(6):580-587. (Pubitemid 350307182)
105. Brown L, Payne S, Royle G. Patient initiated follow up of breast cancer. Psychooncology. 2002;11(4):346-355. (Pubitemid 34987592)
106. Wyatt GK, Donze LF, Beckrow KC. Efficacy of an in-home nursing intervention following short-stay breast cancer surgery. Res Nurs Health. 2004;27(5):322-331. (Pubitemid 39434261)
107. Koinberg IL, Fridlund B, Engholm GB, Holmberg L. Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs. 2004;8(2):109-117. (Pubitemid 38811747)
108. Sheppard C, Higgins B, Wise M, Yiangou C, Dubois D, Kilburn S. Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6-monthly clinical review. Eur J Oncol Nurs. 2009;13(1):2-8.
109. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;70(1):1-10. (Pubitemid 33105097)
110. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy [review]. Clin Breast Cancer. 2002;3(suppl 3):S116-S120.
111. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5(6):439-446.
112. Olsson AM, Svensson JH, Sundstrom J, et al. Erythropoietin treatment in metastatic breast cancer-effects on Hb, quality of life and need for transfusion. Acta Oncologica. 2002;41(6):517-524. (Pubitemid 36061321)
113. Williams AF, Vadgama A, Franks PJ, Mortimer PS. A randomized controlled crossover study of manual lymphatic drainage therapy in women with breast cancer-related lymphoedema. Eur J Cancer Care. 2002;11(4):254-261.
114. Schmuth M, Wimmer MA, Hofer S, et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br J Dermatol. 2002;146(6):983-991. (Pubitemid 34779478)
115. Carpenter JS, Wells N, Lambert B, et al. A pilot study of magnetic therapy for hot flashes after breast cancer. Cancer Nurs. 2002;25(2):104-109. (Pubitemid 34263934)
116. Schneider SM, Ellis M, Coombs WT, Shonkwiler EL, Folsom LC. Virtual reality intervention for older women with breast cancer. Cyberpsychol Behav. 2003;6(3):301-307. (Pubitemid 36753992)
117. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003;101(6):1213-1220. (Pubitemid 36694346)
118. McKenzie DC, Kalda AL. Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. J Clin Oncol. 2003;21(3):463-466. (Pubitemid 46606476)
119. Gothard L, Cornes P, Earl J, et al. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol. 2004;73(2):133-139. (Pubitemid 39470151)
120. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111(3):306-312. (Pubitemid 39201152)
121. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2004;24(2C):1293-1302. (Pubitemid 38624978)
122. Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2005;23(25):6027-6036.
123. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study [see comment]. J Clin Oncol. 2005;23(25):5960-5972.
124. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92(10):1869-1876. (Pubitemid 40826135)
125. Roscoe JA, Matteson SE, Morrow GR, et al. Acustimulation wrist bands are not effective for the control of chemotherapy-induced nausea in women with breast cancer. J Pain Symptom Manage. 2005;29(4):376-384. (Pubitemid 40602518)
126. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy [see comment] [erratum appears in J Clin Oncol. 2005 Aug 1;23(22):5276]. J Clin Oncol. 2005;23(12):2597-2605. (Pubitemid 46179448)
127. MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005;41(5):708-714. (Pubitemid 40342553)
128. Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89(3):243-249. (Pubitemid 43293071)
129. Jacobs J, Herman P, Heron K, Olsen S, Vaughters L. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial [see comment]. J Altern Complement Med. 2005;11(1):21-27. (Pubitemid 40328113)
130. Thompson EA, Montgomery A, Douglas D, Reilly D. A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors [see comment]. J Altern Complement Med. 2005;11(1):13-20. (Pubitemid 40328112)
131. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12(2):114-122.
132. Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2006;26(2B):1519-1529.
133. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007;12(1):124-135. (Pubitemid 46150798)
134. Robb KA, Newham DJ, Williams JE. Transcutaneous electrical nerve stimulation vs. transcutaneous spinal electroanalgesia for chronic pain associated with breast cancer treatments. J Pain Symptom Manage. 2007;33(4):410-419. (Pubitemid 46505073)
135. De Souza Fede AB, Bensi CG, Trufelli DC, et al. Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol. 2007;30(4):432-436. (Pubitemid 47356689)
136. Mar Fan HG, Clemons M, Xu W, et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008;16(6):577-583.
137. Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008;112(1):197-201.
138. Yeo W, Mo FKF, Suen JJS, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529-535.
139. Buijs C, Mom CH, Willemse PHB, et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat. 2009;115(3):573-580.
140. Carpenter JS, Yu M, Wu J, et al. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. Menopause. 2009;16(4):644-652.
141. Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization [see comment]. Cancer Pract. 2001;9(1):19-26.
142. Edgar L, Rosberger Z, Collet JP. Lessons learned: outcomes and methodology of a coping skills intervention trial comparing individual and group formats for patients with cancer. Int J Psychiatry Med. 2001;31(3):289-304. (Pubitemid 34121041)
143. Helgeson VS, Cohen S, Schulz R, Yasko J. Long-term effects of educational and peer discussion group interventions on adjustment to breast cancer [see comment]. Health Psychol. 2001;20(5):387-392. (Pubitemid 32843989)
144. Gustafson DH, Hawkins R, Pingree S, et al. Effect of computer support on younger women with breast cancer. J Gen Intern Med. 2001;16(7):435-445. (Pubitemid 34208919)
145. Allen SM, Shah AC, Nezu AM, et al. A problem-solving approach to stress reduction among younger women with breast carcinoma: a randomized controlled trial. Cancer. 2002;94(12):3089-3100. (Pubitemid 34670491)
146. Kissane DW, Bloch S, Smith GC, et al. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psychooncology. 2003;12(6):532-546. (Pubitemid 37086729)
147. Kissane DW, Love A, Hatton A, et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol. 2004;22(21):4255-4260. (Pubitemid 41185146)
148. Taylor KL, Lamdan RM, Siegel JE, Shelby R, Moran-Klimi K, Hrywna M. Psychological adjustment among African American breast cancer patients: one-year follow-up results of a randomized psychoeducational group intervention. Health Psychol. 2003;22(3):316-323. (Pubitemid 36576456)
149. Angell KL, Kreshka MA, McCoy R, et al. Psychosocial intervention for rural women with breast cancer: the Sierra-Stanford Partnership. J Gen Intern Med. 2003;18(7):499-507. (Pubitemid 36921016)
150. Fukui S, Koike M, Ooba A, Uchitomi Y. The effect of a psychosocial group intervention on loneliness and social support for Japanese women with primary breast cancer. Oncol Nurs Forum. 2003;30(5):823-830.
151. Fukui S, Kugaya A, Okamura H, et al. A psychosocial group intervention for Japanese women with primary breast carcinoma. Cancer. 2000;89(5):1026-1036.
152. Heiney SP, McWayne J, Hurley TG, et al. Efficacy of therapeutic group by telephone for women with breast cancer. Cancer Nurs. 2003;26(6):439-447. (Pubitemid 37543037)
153. Hack TF, Pickles T, Bultz BD, et al. Impact of providing audiotapes of primary adjuvant treatment consultations to women with breast cancer: a multisite, randomized, controlled trial. J Clin Oncol. 2003;21(22):4138-4144. (Pubitemid 46606181)
154. Sandgren AK, McCaul KD. Short-term effects of telephone therapy for breast cancer patients. Health Psychol. 2003;22(3):310-315. (Pubitemid 36576455)
155. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol. 2004;22(17):3570-3580. (Pubitemid 41103664)
156. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun. 2007;21(7):953-961. (Pubitemid 47299295)
157. Hidderley M, Holt M. A pilot randomized trial assessing the effects of autogenic training in early stage cancer patients in relation to psychological status and immune system responses. Eur J Oncol Nurs. 2004;8(1):61-65. (Pubitemid 38351226)
158. Yoo HJ, Ahn SH, Kim SB, Kim WK, Han OS. Efficacy of progressive muscle relaxation training and guided imagery in reducing chemotherapy side effects in patients with breast cancer and in improving their quality of life. Support Care Cancer. 2005;13(10):826-833. (Pubitemid 41414024)
159. Owen JE, Klapow JC, Roth DL, et al. Randomized pilot of a self-guided internet coping group for women with early-stage breast cancer. Ann Behav Med. 2005;30(1):54-64. (Pubitemid 41208986)
160. Walker MS, Podbilewicz-Schuller Y. Video preparation for breast cancer treatment planning: results of a randomized clinical trial. Psychooncology. 2005;14(5):408-420. (Pubitemid 40674418)
161. Miyashita M. A randomized intervention study for breast cancer survivors in Japan: effects of short-term support group focused on possible breast cancer recurrence. Cancer Nurs. 2005;28(1):70-78. (Pubitemid 40250627)
162. Antoni MH, Lechner SC, Kazi A, et al. How stress management improves quality of life after treatment for breast cancer. J Consult Clin Psychol. 2006;74(6):1143-1152. (Pubitemid 44950837)
163. Svensk AC, Oster I, Thyme KE, et al. Art therapy improves experienced quality of life among women undergoing treatment for breast cancer: a randomized controlled study. Eur J Cancer Care. 2009;18(1):69-77.
164. Classen C, Butler LD, Koopman C, et al. Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial. Arch Gen Psychiatry. 2001;58(5):494-501. (Pubitemid 32411331)
165. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer. 2007;110(5):1130-1138. (Pubitemid 47312880)
166. Bordeleau L, Szalai JP, Ennis M, et al. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. J Clin Oncol. 2003;21(10):1944-1951. (Pubitemid 46606382)
167. Lemieux J, Beaton DE, Hogg-Johnson S, Bordeleau LJ, Hunter J, Goodwin PJ. Responsiveness to change due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. Qual Life Res. 2007;16(6):1007-1017. (Pubitemid 47179824)
168. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345(24):1719-1726.
169. Northouse L, Kershaw T, Mood D, Schafenacker A. Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers. Psychooncology. 2005;14(6):478-491. (Pubitemid 40883419)
170. Aranda S, Schofield P, Weih L, Milne D, Yates P, Faulkner R. Meeting the support and information needs of women with advanced breast cancer: a randomised controlled trial. Br J Cancer. 2006;95(6):667-673. (Pubitemid 44373479)
171. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007;16(4):277-286. (Pubitemid 46681097)
172. Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer. 2002;10(3):237-246. (Pubitemid 36056298)
173. Williams SA, Schreier AM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer [online]. Oncol Nurs Forum. 2004;31(1):E16-E23.
174. Schneider SM, Prince-Paul M, Allen MJ, Silverman P, Talaba D. Virtual reality as a distraction intervention for women receiving chemotherapy [online]. Oncol Nurs Forum. 2004;31(1):81-88.
175. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part II: immunologic effects. J Clin Oncol. 2005;23(25):6097-6106.
176. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol. 2005;23(25):6083-6096.
177. Roscoe JA, Matteson SE, Mustian KM, Padmanaban D, Morrow GR. Treatment of radiotherapy-induced fatigue through a nonpharmacological approach. Integr Cancer Ther. 2005;4(1):8-13. (Pubitemid 40250672)
178. Raghavendra RM, Nagarathna R, Nagendra HR, et al. Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care. 2007;16(6):462-474.
179. Crew KD, Capodice JL, Greenlee H, et al. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. J Cancer Surviv. 2007;1(4):283-291.
180. Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs. 2008;61(6):664-675.
181. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022-5026.
182. Heidrich SM, Brown RL, Egan JJ, et al. An individualized representational intervention to improve symptom management (IRIS) in older breast cancer survivors: three pilot studies. Oncol Nurs Forum. 2009;36(3):E133-E143.
183. Segal R, Evans W, Johnson D, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol. 2001;19(3):657-665. (Pubitemid 32119079)
184. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes [see comment]. J Clin Oncol. 2003;21(9):1660-1668. (Pubitemid 46638575)
185. Headley JA, Ownby KK, John LD. The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer [online]. Oncol Nurs Forum. 2004;31(5):977-983.
186. Mustian KM, Katula JA, Gill DL, Roscoe JA, Lang D, Murphy K. Tai Chi Chuan, health-related quality of life and self-esteem: a randomized trial with breast cancer survivors. Support Care Cancer. 2004;12(12):871-876. (Pubitemid 40104783)
187. Sandel SL, Judge JO, Landry N, Faria L, Ouellette R, Majczak M. Dance and movement program improves quality-of-life measures in breast cancer survivors. Cancer Nurs. 2005;28(4):301-309. (Pubitemid 41098336)
188. Pinto BM, Frierson GM, Rabin C, Trunzo JJ, Marcus BH. Home-based physical activity intervention for breast cancer patients. J Clin Oncol. 2005;23(15):3577-3587.
189. Campbell A, Mutrie N, White F, McGuire F, Kearney N. A pilot study of a supervised group exercise programme as a rehabilitation treatment for women with breast cancer receiving adjuvant treatment. Eur J Oncol Nurs. 2005;9(1):56-63. (Pubitemid 40361586)
190. Ohira T, Schmitz KH, Ahmed RL, Yee D. Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. Cancer. 2006;106(9):2076-2083. (Pubitemid 43673225)
191. Herrero F, San Juan AF, Fleck SJ, et al. Combined aerobic and resistance training in breast cancer survivors: a randomized, controlled pilot trial. Int J Sports Med. 2006;27(7):573-580. (Pubitemid 44047994)
192. Basen-Engquist K, Taylor CLC, Rosenblum C, et al. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns. 2006;64(1-3):225-234. (Pubitemid 44772961)
193. Beurskens CHG, Van Uden CJT, Strobbe LJA, Oostendorp RAB, Wobbes T. The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer, a randomized controlled study. BMC Cancer. 2007;7:166.
194. Banerjee B, Vadiraj HS, Ram A, et al. Effects of an integrated yoga program in modulating psychological stress and radiation-induced genotoxic stress in breast cancer patients undergoing radiotherapy. Integr Cancer Ther. 2007;6(3):242-250. (Pubitemid 47301121)
195. Badger T, Segrin C, Dorros SM, Meek P, Lopez AM. Depression and anxiety in women with breast cancer and their partners. Nurs Res. 2007;56(1):44-53.
196. Heim ME, Niklas A. Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue. Onkologie. 2007;30(8-9):429-434. (Pubitemid 350194939)
197. Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol. 2007;25(28):4387-4395. (Pubitemid 350013844)
198. Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007;25(28):4396-4404. (Pubitemid 350013845)
199. Courneya KS, Segal RJ, Gelmon K, et al. Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2572-2578. (Pubitemid 351196311)
200. Vallance JKH, Courneya KS, Plotnikoff RC, Yasui Y, Mackey JR. Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol. 2007;25(17):2352-2359. (Pubitemid 46999206)
201. Vallance JK, Courneya KS, Plotnikoff RC, Dinu I, Mackey JR. Maintenance of physical activity in breast cancer survivors after a randomized trial. Med Sci Sports Exerc. 2008;40(1):173-180.
202. Mutrie N, Campbell AM, Whyte F, et al. Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ. 2007;334(7592):517.
203. Lee TS, Kilbreath SL, Refshauge KM, Pendlebury SC, Beith JM, Lee MJ. Pectoral stretching program for women undergoing radiotherapy for breast cancer. Breast Cancer Res Treat. 2007;102(3):313-321. (Pubitemid 46474844)
204. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A. Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol. 2007;25(13):1713-1721. (Pubitemid 46797952)
205. Demark-Wahnefried W, Case LD, Blackwell K, et al. Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. Clini Breast Cancer. 2008;8(1):70-79. (Pubitemid 351346232)
206. Mustian KM, Palesh OG, Flecksteiner SA. Tai Chi Chuan for breast cancer survivors. Med Sport Sci. 2008;52:209-217.
207. Milne HM, Wallman KE, Gordon S, Courneya KS. Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2008;108(2):279-288. (Pubitemid 351311368)
208. Fillion L, Gagnon P, Leblond F, et al. A brief intervention for fatigue management in breast cancer survivors. Cancer Nurs. 2008;31(2):145-159.
209. Hwang JH, Chang HJ, Shim YH, et al. Effects of supervised exercise therapy in patients receiving radiotherapy for breast cancer. Yonsei Med J. 2008;49(3):443-450.
210. Rogers LQ, Hopkins-Price P, Vicari S, et al. A randomized trial to increase physical activity in breast cancer survivors. Med Sci Sports Exerc. 2009;41(4):935-946.
211. Rogers LQ, Hopkins-Price P, Vicari S, et al. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1410-1418.
212. Danhauer SC, Mihalko SL, Russell GB, et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology. 2009;18(4):360-368.
213. Targ EF, Levine EG. The efficacy of a mind-body-spirit group for women with breast cancer: a randomized controlled trial. Gen Hosp Psychiatry. 2002;24(4):238-248. (Pubitemid 34718150)
214. Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant. 2003;32(7):715-721. (Pubitemid 37258628)
215. Wells M, Harrow A, Donnan P, et al. Patient, carer and health service outcomes of nurse-led early discharge after breast cancer surgery: a randomised controlled trial. Br J Cancer. 2004;91(4):651-658. (Pubitemid 39141619)
216. Van Roosmalen MS, Stalmeier PF, Verhoef LC, et al. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. J Clin Oncol. 2004;22(16):3293-3301. (Pubitemid 41103685)
217. Van Roosmalen MS, Stalmeier PF, Verhoef LC, et al. Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. Br J Cancer. 2004;90(2):333-342. (Pubitemid 38250625)
218. Scheier MF, Helgeson VS, Schulz R, et al. Interventions to enhance physical and psychological functioning among younger women who are ending nonhormonal adjuvant treatment for early-stage breast cancer. J Clin Oncol. 2005;23(19):4298-4311. (Pubitemid 46207004)
219. Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. J Clin Oncol. 2005;23(25):6009-6018.
220. Cho O-H, Yoo Y-S, Kim N-C. Efficacy of comprehensive group rehabilitation for women with early breast cancer in South Korea. Nurs Health Sci. 2006;8(3):140-146. (Pubitemid 44145063)
221. Meneses KD, McNees P, Loerzel VW, Su X, Zhang Y, Hassey LA. Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors. Oncol Nurs Forum. 2007;34(5):1007-1016.
222. Loerzel VW, McNees P, Powel LL, Su X, Meneses K. Quality of life in older women with early-stage breast cancer in the first year of survivorship. Oncol Nurs Forum. 2008;35(6):924-932.
223. Sandgren AK, McCaul KD. Long-term telephone therapy outcomes for breast cancer patients. Psychooncology. 2007;16(1):38-47. (Pubitemid 46189076)
224. Meneses K, McNees P, Azuero A, Loerzel VW, Su X, Hassey LA. Preliminary evaluation of psychoeducational support interventions on quality of life in rural breast cancer survivors after primary treatment. Cancer Nurs. 2009;32(5):385-397.
225. Low CA, Stanton AL, Danoff-Burg S. Expressive disclosure and benefit finding among breast cancer patients: mechanisms for positive health effects. Health Psychol. 2006;25(2):181-189.
226. Arving C, Sjoden P-O, Bergh J, et al. Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care. Cancer Nurs. 2007;30(3):E10-E19. (Pubitemid 47233890)
227. Arving C, Sjoden P-O, Bergh J, et al. Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients-a randomised study of nurse versus psychologist interventions. Patient Educ Couns. 2006;62(2):235-243. (Pubitemid 43975707)
228. Dragan S, Nicola T, Ilina R, et al. Role of multi-component functional foods in the complex treatment of patients with advanced breast cancer. Rev Med Chir Soc Med Nat Iasi. 2007;111(4):877-884.
229. Billhult A, Bergbom I, Stener-Victorin E. Massage relieves nausea in women with breast cancer who are undergoing chemotherapy. J Altern Complement Med. 2007;13(1):53-57.
230. Hartmann U, Muche R, Reuss-Borst M. Effects of a step-by-step inpatient rehabilitation programme on quality of life in breast cancer patients. A prospective randomised study. Onkologie. 2007;30(4):177-182. (Pubitemid 46482160)
231. Gotay CC, Moinpour CM, Unger JM, et al. Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. J Clin Oncol. 2007;25(15):2093-2099. (Pubitemid 46972796)
232. Titeca G, Poot F, Cassart D, et al. Impact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiotherapy: an initial randomized controlled study. J Eur Acad Dermatol Venereol. 2007;21(6):771-776. (Pubitemid 46939049)
233. Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage. 2008;35(4):397-405. (Pubitemid 351400364)
234. Billhult A, Lindholm C, Gunnarsson R, Stener-Victorin E. The effect of massage on cellular immunity, endocrine and psychological factors in women with breast cancer - a randomized controlled clinical trial. Auton Neurosci. 2008;140(1-2):88-95.
235. Lindemalm C, Mozaffari F, Choudhury A, et al. Immune response, depression and fatigue in relation to support intervention in mammary cancer patients. Support Care Cancer. 2008;16(1):57-65. (Pubitemid 350243759)
236. Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psychooncology. 2009;18(4):343-352.
237. Irwin ML, Cadmus L, Alvarez-Reeves M, et al. Recruiting and retaining breast cancer survivors into a randomized controlled exercise trial: the Yale Exercise and Survivorship Study. Cancer. 2008;112(11):2593-2606.
238. Berger AM, Kuhn BR, Farr LA, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology. 2009;18(6):634-646.
239. Berger AM, Lockhart K, Agrawal S. Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. Oncol Nurs Forum. 2009;36(5):563-570.
240. Dolbeault S, Cayrou S, Brédart A, et al. The effectiveness of a psycho-educational group after early-stage breast cancer treatment: results of a randomized French study. Psychooncology. 2009;18(6):647-656.
241. Joreskog K, Sorbom D. PRELIS 2: User's Reference Guide.Chicago, IL: Scientific software international Inc; 1996.
242. Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol. 2009;27(2):274-296.
243. Nidich SI, Fields JZ, Rainforth MV, et al. A randomized controlled trial of the effects of transcendental meditation on quality of life in older breast cancer patients. Integr Cancer Ther. 2009;8(3):228-234.
244. Liu J, Tu D, Dancey J, et al. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19. Breast Cancer Res Treat. 2006;100(3):263-271. (Pubitemid 44707920)
245. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091-5097. (Pubitemid 46631413)
246. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-4057. (Pubitemid 46606220)
247. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2(8668):888-891.
248. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials. Br Cancer Res Treat. 2007;106(suppl 1):S5.
249. Kazdin AE. Evidence-based treatment and practice: new opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care. Am Psychol. 2008;63(3):146-159.